OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Motzer on the Importance of Assessing Health-Related QOL in RCC

July 20th 2021

Robert J. Motzer, MD, discusses the importance of assessing health-related quality of life in renal cell carcinoma.

Dr. Ahmed on Optimizing Treatment With Axi-Cel in LBCL

July 20th 2021

Sairah Ahmed, MD, discusses optimizing treatment with axicabtagene ciloleucel in large B-cell lymphoma.

Dr. Ghia on Key Findings From the CAPTIVATE Trial in CLL

July 19th 2021

Paolo Ghia, MD, PhD, discusses key findings from the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Verstovsek on Efficacy of Pelabresib Plus Ruxolitinib in Myelofibrosis

July 19th 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy of the combination of pelabresib plus ruxolitinib in the treatment of patients with myelofibrosis.

Dr. Flowers on Long-Term Efficacy With Tafasitamab Plus Lenalidomide in DLBCL

July 19th 2021

Christopher Flowers, MD, discusses the long-term efficacy with tafasitamab-cxix in combination with lenalidomide in diffuse large B-cell lymphoma.

Dr. Ma on First-Line Treatment Considerations in Metastatic Pancreatic Cancer

July 19th 2021

Wen Wee Ma, MBBS, discusses first-line treatment considerations in metastatic pancreatic cancer.

Dr. Lyou on Emerging Biomarkers in Prostate Cancer

July 19th 2021

Yung Lyou, MD, PhD, discusses emerging biomarkers in prostate cancer.

Dr. O’Donnell on the Promise of Novel Targets in Multiple Myeloma

July 19th 2021

Betsy O'Donnell, MD, discusses the promise of novel targets in multiple myeloma.

Dr. Thomas on the Safety Profile of Lifileucel Plus Pembrolizumab in Advanced Melanoma

July 19th 2021

Sajeve Samuel Thomas, MD, discusses the safety profile of lifileucel plus pembrolizumab in advanced melanoma.

Dr. Tolaney on Tailoring HER2-Directed Therapy in Breast Cancer

July 19th 2021

Sara M. Tolaney, MD, MPH, discusses tailoring HER2-directed therapies in the treatment of patients with breast cancer.

Dr. Chase on Utilizing Genetic Testing to Guide Treatment Decisions in Ovarian Cancer

July 19th 2021

Dana Chase, MD, FACOG, discusses the importance of utilizing genetic testing to guide treatment decisions for patients with ovarian cancer.

Dr. Shirasu on the Design for the GALAXY Trial Examining ctDNA in CRC

July 19th 2021

Hiromichi Shirasu, MD, discusses the design of the GALAXY trial, part of the CIRCULATE-Japan project, which is examining circulating tumor DNA in patients with resectable colorectal cancer.

Dr. Pollyea on Indications for Anti-CD33 Therapy in AML

July 19th 2021

Daniel Pollyea, MD, MS, discusses indications for anti-CD33 therapy in the treatment of patients with acute myeloid leukemia.

Dr. Atallah on the Clinical Implications of the QUAZAR AML-001 Trial in AML

July 16th 2021

Ehab L. Atallah, MD, discusses the clinical implications of the phase 3 QUAZAR AML-001 trial in acute myeloid leukemia.

Dr. Smith on the Rationale of the ECOG-ACRIN E1411 Trial in MCL

July 16th 2021

Mitchell R. Smith, MD, PhD, discusses the rationale for the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Dr. Lyou on Sequencing Apalutamide in Prostate Cancer

July 16th 2021

Yung Lyou, MD, PhD, discusses optimal sequencing with apalutamide in prostate cancer.

Dr. Barr on the Implications of the Long-Term Results of the RESONATE-2 Trial in CLL

July 15th 2021

Paul M. Barr, MD, discusses the clinical implications of the long-term results of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. Martin on the Role of Maintenance Therapy With Rituximab in MCL

July 15th 2021

Peter Martin, MD, discusses the role of maintenance therapy with rituximab in mantle cell lymphoma.

Dr. Nadeem on the Uptake of Novel Therapies in Heavily Pretreated Multiple Myeloma

July 15th 2021

Omar Nadeem, MD, discusses the uptake of novel therapies in heavily pretreated multiple myeloma.

Dr. Sperling on Future Research With CAR T-Cell Therapy in Multiple Myeloma

July 14th 2021

Adam Sperling, MD, PhD, discusses future research with CAR T-cell therapy in multiple myeloma.